Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
Mon, 08.01.2024
Evotec SE
KEY SCIENTIFIC ACHIEVEMENT ADVANCES THE JOINT NEUROSCIENCE PIPELINE AND EARNS A PAYMENT OF US$ 25 M TO EVOTEC TO PROGRESS FURTHER RESEARCH
Hamburg, Germany, 08 January 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced progress within the Company’s strategic partnership with Bristol Myer [ … ]
Mon, 08.01.2024
Northern Data AG
PRESS RELEASE / IR NEWS
Northern Data Group announces closing of Damoon acquisition
Major progress in the execution of Northern Data Group‘s vision to become the world’s leading High-Performance Computing (HPC) Infrastructure Solutions Provider
Northern Data Group now owns 100% of Damoon
Aroosh Thillainathan, Founder and CEO, has announced tha [ … ]
Mon, 08.01.2024
SoftwareONE Holding AG
Media Release – ad hoc announcement pursuant to Art. 53 LR
SoftwareOne welcomes Rohit Nagarajan as Chief Revenue Officer
Stans, Switzerland I 8 January 2024 – SoftwareOne Holding AG, a leading global software and cloud solutions provider, today welcomed Rohit Nagarajan as President and Chief Revenue Officer, and a member of the Executive Board wi [ … ]
Mon, 08.01.2024
SoftwareONE Holding AG
Media Release – ad hoc announcement pursuant to Art. 53 LR
SoftwareOne response to media reports and update on strategic review
Stans, Switzerland I 8 January 2024 – In response to media reports, the Board of Directors of SoftwareOne Holding AG, a leading global software and cloud solutions provider, confirms that, as part of its ongoing strategi [ … ]
Sun, 07.01.2024
QIAGEN N.V.
Ad hoc Announcement according to Art. 17 Market Abuse Regulation
QIAGEN to return approximately $300 million to shareholders through a synthetic share repurchase
Venlo, the Netherlands, January 7, 2024 – QIAGEN N.V. announces a plan to return up to approximately $300 million (maximum EUR 273 million) to shareholders through a synthetic share repu [ … ]
Fri, 05.01.2024
STEICO SE
Changes to the Administrative Board of STEICO SE as part of the sale of the majority shares in STEICO SE.
Feldkirchen near Munich, 5 January 2024 – (ISIN DE000A0LR936) – As already stated in the ad hoc announcement of 17 July 2023, the sale of the majority shares in STEICO SE by Schramek GmbH to the Irish Kingspan Group will result in changes to t [ … ]
Fri, 05.01.2024
Mutares SE & Co. KGaA
First exit in 2024: Mutares has successfully sold VALTI to the company’s management
Munich, January 5, 2024 – Mutares SE & Co. KGaA (ISIN: DE000A2NB650) has successfully sold its portfolio company VALTI to the company’s management.
VALTI is a European manufacturer of seamless high-precision steel tubes serving the bearing manufacturer industr [ … ]
Fri, 05.01.2024
CureVac
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
Head-to-head comparison with licensed bivalent mRNA-based comparator vaccine confirms competitive immune responses at lower doses and favorable tolerability profile
M [ … ]
Fri, 05.01.2024
Immunic, Inc.
Immunic Highlights 2023 Accomplishments and Upcoming Milestones
– Evidence for Neuroprotective Activity of Vidofludimus Calcium from Phase 2 CALLIPER Interim Analysis, Consistent Across the Entire Progressive Multiple Sclerosis Population and All Subtypes –
– Phase 3 ENSURE Program in Relapsing Multiple Sclerosis Ongoing –
– Improvements in Gut [ … ]
Fri, 05.01.2024
Immunic, Inc.
Immunic, Inc. Announces Private Placement of up to $240 Million
NEW YORK, January 5, 2024 – Immunic, Inc. (Nasdaq: IMUX) (“Immunic” or the “Company”), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced it has entered into a securi [ … ]